Evaluation of the effects of resveratrol and bevacizumab on experimental corneal alkali burn.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 22922008.
- Also identified by DOI 10.1016/j.burns.2012.07.018.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To evaluate the effects of resveratrol and bevacizumab on experimental corneal neovascularization. A corneal alkali burn was performed in 62 eyes of 31 male white Vienna rabbits. Resveratrol (group 1), dimethyl sulfoxide (group 2), bevacizumab (group 3) and 0.9% NaCl (group 4) were administered to both eyes of the rabbits by subconjunctival injection for 7 days. Corneal photos were taken at 15 days after alkali injury. Inflammatory index scores and neovascularization areas were calculated. In bevacizumab group both inflammatory index scores and the calculation of the corneal neovascularization area was significantly less than the groups. The subconjunctival administration of bevacizumab inhibits corneal neovascularization effectively in the rabbit corneal alkali burn model. No effect of resveratrol to the corneal neovascularization on experimental model of the corneal alkali burn was seen at the doses of usage.
Medical subject headings
- Angiogenesis Inhibitors
- Anti-Inflammatory Agents, Non-Steroidal
- Antibodies, Monoclonal, Humanized
- Burns, Chemical
- Corneal Neovascularization
- Eye Burns
- Stilbenes